JP2023504904A5 - - Google Patents

Info

Publication number
JP2023504904A5
JP2023504904A5 JP2022534636A JP2022534636A JP2023504904A5 JP 2023504904 A5 JP2023504904 A5 JP 2023504904A5 JP 2022534636 A JP2022534636 A JP 2022534636A JP 2022534636 A JP2022534636 A JP 2022534636A JP 2023504904 A5 JP2023504904 A5 JP 2023504904A5
Authority
JP
Japan
Prior art keywords
peptide
arg
conjugate group
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022534636A
Other languages
English (en)
Japanese (ja)
Other versions
JP7796013B2 (ja
JP2023504904A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/134598 external-priority patent/WO2021115272A1/zh
Publication of JP2023504904A publication Critical patent/JP2023504904A/ja
Publication of JP2023504904A5 publication Critical patent/JP2023504904A5/ja
Application granted granted Critical
Publication of JP7796013B2 publication Critical patent/JP7796013B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022534636A 2019-12-09 2020-12-08 カルシウム感知受容体アゴニスト化合物及びその使用 Active JP7796013B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201911250088.1 2019-12-09
CN201911250088 2019-12-09
PCT/CN2020/134598 WO2021115272A1 (zh) 2019-12-09 2020-12-08 钙敏感受体激动剂化合物及其应用

Publications (3)

Publication Number Publication Date
JP2023504904A JP2023504904A (ja) 2023-02-07
JP2023504904A5 true JP2023504904A5 (cg-RX-API-DMAC7.html) 2023-12-14
JP7796013B2 JP7796013B2 (ja) 2026-01-08

Family

ID=76328843

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022534636A Active JP7796013B2 (ja) 2019-12-09 2020-12-08 カルシウム感知受容体アゴニスト化合物及びその使用

Country Status (11)

Country Link
US (1) US20230041996A1 (cg-RX-API-DMAC7.html)
EP (1) EP4091623A4 (cg-RX-API-DMAC7.html)
JP (1) JP7796013B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220110789A (cg-RX-API-DMAC7.html)
CN (2) CN118496313A (cg-RX-API-DMAC7.html)
AU (1) AU2020399030B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022011127A2 (cg-RX-API-DMAC7.html)
CA (1) CA3159744A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022006892A (cg-RX-API-DMAC7.html)
TW (1) TW202122410A (cg-RX-API-DMAC7.html)
WO (1) WO2021115272A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117295510A (zh) * 2021-06-08 2023-12-26 北京拓界生物医药科技有限公司 一种钙敏感受体激动剂的组合物及其应用
TW202313655A (zh) * 2021-06-08 2023-04-01 大陸商北京拓界生物醫藥科技有限公司 鈣敏感受體激動劑化合物的鹽酸鹽及醫藥組成物和其應用
CN121378400A (zh) * 2024-10-24 2026-01-23 成都诺和晟泰生物科技有限公司 一种多肽化合物、包含其的组合物及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050460A1 (es) * 2003-04-23 2005-07-08 Japan Tobacco Inc COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO)
EP2459208B1 (en) * 2009-07-29 2016-09-28 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
CN103270018A (zh) * 2010-11-26 2013-08-28 利奥制药有限公司 钙敏感受体激活化合物
WO2012069421A1 (en) * 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
PT2717896T (pt) * 2011-06-08 2016-12-23 Kai Pharmaceuticals Inc Agentes terapêuticos para a regulação do fósforo sérico
MX355063B (es) * 2011-11-10 2018-04-04 Kai Pharmaceuticals Inc Calcimiméticos y métodos para su uso.

Similar Documents

Publication Publication Date Title
JP5753097B2 (ja) 肥満の治療
JP6204369B2 (ja) カルシウム模倣薬およびその使用方法
JP7381652B2 (ja) バース症候群の予防または治療のための方法及び組成物
CN108472329B (zh) 多肽刺激免疫系统的用途
CN101842101A (zh) 水杨酰苯胺修饰的肽用作口服治疗剂
JP2024178173A (ja) アプラグルチドの製造、配合、及び投薬
CN105579054A (zh) 预防或治疗左心室重塑的方法
WO2014210062A1 (en) Methods for the regulation of matrix metalloproteinase expression
AU2012267470B2 (en) Therapeutic agents for regulating serum phosphorus
EP3003345A1 (en) Angiotensin peptides in treating marfan syndrome and related disorders
AU2012267470A1 (en) Therapeutic agents for regulating serum phosphorus
US20220257711A1 (en) PEPTOID-PEPTIDE HYBRID, NMEG-aCGRP, AND ITS USE IN CARDIOVASCULAR DISEASES
WO2014075137A1 (en) Peptides incorporating amino-substituted lactams for treatment of retinopathy